FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
State releases report on chronic pain procedures
The Minnesota Department of Health has found that about 83,000 Minnesotans a year received chronic pain procedures during a three-year period. MDH was able to conduct this analysis for the ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...
Can new drug promise pain relief without peril?
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
FDA approves opioid-free pain medication with 'no sign of addiction'
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
clinicaladvisor.com11d
Astronauts Experience Acute and Chronic Pain During and After Spaceflight
Astronauts commonly reported acute and chronic pain during and after spaceflight, particularly in the lumbar spine. During and after spaceflight, astronauts experience lower back pain (LBP ...
Axios on MSN5d
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
Time on MSN4d
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...